Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Abstract

BackgroundWe investigated whether combinations of serum cytokines, used with logistic disease predictor models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC).MethodsThe serum levels of 27 cytokines were measured in 241 subjects, 127 with PDAC, 49 with chronic pancreatitis, 20 with benign biliary obstruction and 45 healthy controls. Samples were split randomly into independent training and test sets. Cytokine biomarker panels were selected by identifying the top performing cytokines in best fit logistic regression models during multiple rounds of resampling from the training dataset. Disease prediction by logistic models, built using the resulting cytokine panels, was evaluated with training and test sets and further examined using resampled performance evaluation.ResultsFor the discrimination of PDAC patients from patients with benign disease, a panel of IP-10, IL-6, PDGF plus CA19-9 offered improved diagnostic performance over CA19-9 alone in the training (AUC 0.838 vs. 0.678) and independent test set (AUC 0.884 vs. 0.798). For the discrimination of PDAC from CP, a panel of IL-8, CA19-9, IL-6 and IP-10 offered improved diagnostic performance over CA19-9 alone with the training (AUC 0.880 vs. 0.758) and test set (AUC 0.912 vs. 0.848). Finally, for the discrimination of PDAC in the presence of jaundice from benign controls with jaundice, a panel of IP-10, IL-8, IL-1b and PDGF demonstrated improvement over CA19-9 in the training (AUC 0.810 vs. 0.614) and test set (AUC 0.857 vs. 0.659).ConclusionsThese findings support the potential role for cytokine panels in the discrimination of PDAC from patients with benign pancreatic diseases and warrant additional study.

Comprehensive Analysis of Serum microRNAs in Autoimmune Pancreatitis

“…Alternatively, we conducted the IPA and identified several molecules such as PDGFB and VEGFA resulting from the net effects of differentially expressed miRNAs in AIP. Previous studies have shown that serum PDGF-BB and VEGF levels were altered in CP and pancreatic cancer [37,38,39], but PDGF-BB levels in patients with CP or pancreatic cancer were not different from those in controls in this study. Serum cytokine profiles in patients with AIP are currently unknown.…”

Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer

“…The utility of CA19-9 is limited in patients who are Lewis blood type negative (Lea -b -). Another limitation of CA 19-9 is that it can be falsely elevated in the presence of biliary obstruction [21]. CEA was the only serum glycoprotein used for diagnosing PC.…”

Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer

“…IL-6 is linked to both pancreatic cancer 18-20 and to fatigue and depression 16,19,21 . Elevated levels of IL-6 have been found to be associated with clinical depression in patients with other cancers 15,22,23,24 .…”